AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01682018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung volume reduction using the Zephyr device
Description: lung volume reduction using the Zephyr device
Study NCT01125085 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)
Description: * Patients will be treated with WBRT administering a total dosage of 30 Gy in fractions of 3 Gy~* Dosimetric evaluation with 131I-L19SIP or 124I-L19SIP will be performed to assess eligibility for RIT.~* Patients eligible for RIT will receive a therapeutic dose of 131I-L19SIP.~* Total treatment duration is up to 4 weeks
Study NCT04281628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine group:
Description: Ketamine group: will be administered ketamine in a loading dose of 0.2 mg/kg over 5 min pre incision followed-by an infusion at 0.2 mg/kg/h until the end of surgery.
Study NCT04281628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: where normal saline was administered as a loading dose then infused with same rate of another group, throughout the whole surgery.
Study NCT02797678 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Powersleep
Description: Participants will receive 5 nights of stimulation
Study NCT02797678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powersleep
Description: Participants will receive 5 nights of stimulation
Study NCT02797678 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Powersleep
Description: Participants will receive 5 nights of no stimulation
Study NCT02797678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Powersleep
Description: Participants will receive 5 nights of no stimulation
Study NCT01313013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: question prompt sheet
Study NCT02191046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: squeezable bottle
Description: nasal irrigation twice daily for 2 weeks period
Study NCT02191046 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: syringe 20 ml
Description: nasal irrigation twice daily for 2 weeks
Study NCT02394184 — intervention group
Intervention type: PROCEDURE
Intervention: transcatheter aortic valve replacement
Study NCT03579823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab 100 MG/ML [Humira]
Description: prefilled syringe at a concentration of 100MG/ML and delivering 40MG of adalimumab, as a single dose on day 1 day 1
Study NCT03579823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVT02 100MG/ML
Description: prefilled syringe at a concentration of 100MG/ML delivering 40MG of AVT02, as a single dose on day 1 day 1
Study NCT00571753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid
Description: modified daily isoniazid dose according to NAT2 genotype (appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively).
Study NCT00571753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoniazid
Description: Treatment with a standard isoniazid dose of isoniazid (appr. 5 mg/kg b.w.)
Study NCT02535754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALIVE
Description: The company assigned to this condition offered employees participation in the ALIVE program. This program was validated in a previous worksite-based randomized controlled trial (RCT). A baseline assessment includes questions asking about: presence of children at home, habits related to cooking and eating out, physical activity preferences, stage of readiness of change, and perceived barriers to achieving heath behavior goals. This information provides the basis for immediate feedback and individually-tailored messages that include goal-setting and tips to achieve these goals, interactive features, and health information. Biweekly messages are sent for a total of 48 weeks. Outcome data were based on all individuals who completed the baseline assessment.
Study NCT02535754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCS BCY
Description: The company assigned to this condition participated in a comprehensive year-long workplace wellness program intervention focusing on nutrition, weight control, and physical activity, led by the CCS BCY. The program was modeled after a previous successful CCS BCY tobacco control worksite program. This program stresses the importance of developing social and environmental supports at the worksite to promote behavior change . Such supports could include food availability (e.g., cafeteria and vending machine selections), the built environment (e.g., availability of bike racks); social environment (e.g., group lunchtime walking clubs), and health communications (e.g., company newsletters). Outcome data were based on all individuals who completed the baseline assessment.
Study NCT02535754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALIVE + CCS BCY
Description: The company assigned to this condition received both the ALIVE and CCS BCY programs. Employees were encouraged to take part in both ALIVE and company initiatives, but participation in these activities was based on individual preference. Outcome data were based on all individuals who completed the baseline assessment.
Study NCT06227715 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: universal adhesive
Study NCT04422964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Obturator
Description: Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer
Study NCT04608890 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Eye-tracking video test
Description: An eye-tracking-based test will be administered to patients. It lasts 10 minutes. It consists in several screens passing by to identify objects at a certain time by a mouse clic or touchpad.
Study NCT03354052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-rTMS + Gloreha device
Description: The real rTMS will be delivered using a 8-shaped coil placed over the primary motor cortex (M1). The resting motor threshold (RMT) will be assessed at the place of the first dorsal interosseous (FDI) contralateral to the stimulated cortex. RMT of the FDI will be determined as the lowest strength of TMS needed to elicit 5 or more electromyographic responses ≥50 μV within 10 trials. Stimulation will be applied with frequency 10 Hz and intensity of 90% of RMT. Every session will last 15 minutes and includes 3000 pulses (30 trains of 10 seconds, following intertrain interval of 20 seconds). Rehabilitation programme will last 30 minutes and will be delivered using Gloreha® device, a proprioceptive stimulator under visual feedback. All the subjects enrolled will receive treatments for 2 weeks, 5 days per week.
Study NCT03354052 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham-rTMS + Gloreha device
Description: The sham rTMS will be delivered using a sham stimulator. All procedures will be performed as for the real treatment. Rehabilitation programme will last 30 minutes and will be delivered using Gloreha® device, a proprioceptive stimulator under visual feedback. All the subjects enrolled will receive treatments for 2 weeks, 5 days per week.
Study NCT02940236 — intervention group
Intervention type: OTHER
Intervention: Ultrasound
Description: Before and after patient receives oral multimodal analgesia as per standard of care, two ultrasound scans will be performed (10 minutes apart for each time element).
Study NCT06414876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital dog
Description: The hospital dog always has a well educated dog instructor beside.
Study NCT01872650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Qur
Description: In subjects assigned to the treatment arm, the C-Qur™ Film must be applied beneath the incision. The C-Qur™ film can also be applied to other areas considered to be adhesiogenic (e.g. the dissection site and ostomy site but not around the anastomosis). The number of C-Qur™ Film sheets placed is limited to a maximum area of coverage of 774cm2.
Study NCT00549601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)
Description: Rivastigmine administered transdermally via patches at increasing doses (1 patch/day of 4.6 mg for the first month, changing to 1 patch/day of 9.5 mg for the remaining two months).
Study NCT00549601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine patch (9.5 mg/day)
Description: Rivastigmine administered transdermally via patches at a constant dose (9.5 mg/day for the 3 months of treatment).
Study NCT00549601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine capsules (6 mg to 12 mg/day)
Description: Rivastigmine administered orally, following the same regime as prior to randomization (doses between 6 mg and 12 mg/day), which remained unchanged throughout the 3 months of treatment.
Study NCT02891486 — intervention group
Intervention type: PROCEDURE
Intervention: Spinal surgery
Description: Elective spinal surgery performed
Study NCT00652808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 10 mg tablet by mouth once daily for 6 weeks
Study NCT00652808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: naproxen 500 mg capsule by mouth twice daily for 6 weeks
Study NCT00404924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (vandetanib)
Description: once daily oral tablet
Study NCT00404924 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: standard of care
Study NCT00404924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: standard of care
Study NCT03556397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Description: Sentinel lymph node biopsy will be performed in the patients
Study NCT04028817 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo photobiomodulation
Description: the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied a placebo sublingual laser for 360 s.
Study NCT01672138 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Vein Antrum Isolation
Description: Radio-frequency catheter ablation of pulmonary vein antrum extended to the left atrial posterior wall
Study NCT01672138 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scar homogenization
Description: PVAI + RF energy will be delivered until all abnormal potentials in the low-voltage areas are eliminated.
Study NCT01672138 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-PV triggers ablation
Description: PVAI + Isolation of LA posterior wall + Catheter ablation of triggers originating from extra-PV sites
Study NCT05250765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twistflex retainer
Description: twisted 0.0195 dead-soft coaxial wire (Respond; Ormco, Orange, Calif)
Study NCT05250765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twistflex retainer
Description: twisted 0.0195 dead-soft coaxial wire (Respond; Ormco, Orange, Calif)
Study NCT03556397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary dissection
Description: Axillary dissection procedure will be performed in the patients
Study NCT00080483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone plus somatropin
Description: AndoGel 5 grams transdermally a day for two years Somatropin 2 µg/kg body weight/day for two years
Study NCT00080483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone
Description: AndroGel transdermally 5 g a day for two years
Study NCT01476397 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control infant formula
Description: partially hydrolyzed whey infant formula consumed ad libitum throughout study
Study NCT01476397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test infant formula
Description: partially hydrolyzed whey formula with probiotic
Study NCT01197209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-REIC/Dkk-3
Description: REIC (Reduced Expression in Immortalized Cells) protein is down regulated in a variety of cancer cell lines including prostate tumors. The REIC gene is identical to the Dickkopf-3 (Dkk-3) gene that is a member of the Dickkopf gene family. Ad-REIC/Dkk-3 is designed as a viral vector that delivers a DNA plasmid capable of producing intracellular REIC protein. The expression plasmid includes the full-length human cDNA sequence for REIC. The adenovirus vector is a transport mechanism to infuse the REIC/Dkk-3 plasmid into the cell providing a temporary transfusion of REIC protein.
Study NCT05250765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthoflex retainer
Description: Ortho-flextech (Reliance orthodontic products, Itasca III, USA)
Study NCT05250765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthoflex retainer
Description: Ortho-flextech (Reliance orthodontic products, Itasca III, USA)
Study NCT02788266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft+composite resin
Description: treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus composite resin
Study NCT02788266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft+ glass ionomer
Description: treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus resin modified glass ionomer cement
Study NCT02788266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft+giomer
Description: treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus giomer
Study NCT03024996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg IV infusion q3w
Study NCT03024996 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to atezolizumab q3w
Study NCT03499561 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: urine analysis
Description: Intervention is (urine analysis ): of a mid stream urine sample will be taken
Study NCT03292445 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immune tolerance after kidney transplant
Description: Induction of immune tolerance after kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and anti-thymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no kidney rejection.
Study NCT03292445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donor blood stem cells and T cells
Description: Immune tolerance after kidney transplantation resulting from mixed blood cells chimerism will be induced by donor blood stem cells and T cells given to the kidney recipient. Donor cells will be collected by apheresis after mobilization of blood stem cells from bone marrow 6-8 weeks before kidney transplant. Collected cells will undergo CD34 selection to recover >10 million donor blood stem cells/kg of patient weight to be combined with up to 150 million donor T cells/kg for transfusion soon after kidney transplant. The IND for this study covers the infusion of donor blood stem cells.
Study NCT00709397 — intervention group
Intervention type: OTHER
Intervention: blood drawing
Description: Subjects will have been prescribed raltegravir (400 mg BID) by their primary physicians. Such subjects will have frequent blood sampling in this study to monitor the virologic response to raltegravir therapy.
Study NCT04221789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TB treatment assistant
Description: Cell phone app to support self administered treatment and monitor adherence
Study NCT04427176 — intervention group
Intervention type: DEVICE
Intervention: ARFC mask
Description: Nurse will wear the ARFC mask during working days. The total duration of the study will be 48 hours for each participant, 2 consecutive working days of 8 or 12 hours.
Study NCT00682227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTK, LY6K, and IMP-3 peptides
Description: Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
Study NCT04042753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg every 3 weeks,
Study NCT04042753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 1 mg/kg every 3 weeks for 4 cycles
Study NCT04042753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Following concurrent ipilimumab and nivolumab, patients will receive single agent nivolumab at 480 mg every 4 weeks for 6 cycles (1 cycle=4 weeks) with the option of continuing until disease progression or until the end of the study, whichever occurs first
Study NCT01459146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination plus albendazole
Description: AL: 20mg/120mg 12-hourly orally for 3 days ABZ: 400mg oral stat
Study NCT01459146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine plus Praziquantel plus Albendazole
Description: Artemether-lumefantrine 20mg/120mg 12 hourly for 3 days, plus praziquantel 40mg/kg stat, plus albendazole 400mg stat oral
Study NCT01459146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole plus Praziquantel
Description: Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
Study NCT00891046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab
Study NCT00573456 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared Radiation
Description: Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes per session.
Study NCT00362375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Love Workshop
Description: The Healthy Love Workshop is a single-session intervention lasting 3-4 h that is typically delivered to groups of 4-15 women; however, SisterLove facilitators can accommodate larger groups if needed. The intervention is designed to increase consistent use of condoms and other latex barriers, reduce unprotected sex with male partners, and reduce the number of sex partners. HLW also promotes sexual abstinence, HIV testing, and receipt of test results.
Study NCT00362375 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV/AIDS 101 Workshop
Description: The comparison workshop (named HIV101) was also delivered as a single session lasting 2-3 h, to groups of women about the same size and in settings similar to those used for the HLW. The HIV101 workshop consists of an opening, one module containing the same three HIV/STD-related components as the HLW (HIV/AIDS facts, STI facts, and the Look of HIV) and a closing. However, the presentation of this information used a didactic, lecture-style format, as opposed to the interactive approach used to deliver the HLW.
Study NCT03215953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cast shoe
Description: ankle-high, custom-made, well-moulded cast shoe
Study NCT03215953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: removable walker
Description: Prefabricated especially designed for relieving load on the foot
Study NCT00522743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: growth hormone and gonadotropin-releasing hormone agonist
Description: GH \& GNRHa treatment
Study NCT00522743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: growth hormone
Description: GH treatment
Study NCT01710059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Supervision
Description: Each participant will be provided with a spacer and a peak flow meter, and instructions on proper technique, by a member of the study team during the baseline period. They will also meet with study staff at study visits during the active treatment phase to review their adherence to daily inhaled corticosteroids and usage patterns of short acting B2-agonist medication.
Study NCT01710059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Phone
Description: Each participant will receive a mobile phone with talking, texting and a data plan. They will get to keep the mobile phone at the end of the study, but the talking, texting and data plan will only be active during their participation in the study.
Study NCT00642954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 300 mg or 400 mg QD via oral capsule on Days 1-7 and Days 15-21 of each 28-day cycle.
Study NCT00642954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 10 mg, 15 mg, 20 mg or 25 mg QD via oral capsule on Days 1-21 of each 28-day cycle.
Study NCT00642954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg QD via oral tablet on Days 1, 8, 15 and 22 of each 28-day cycle.
Study NCT02641405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Equistasi
Description: Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive three patches to be placed at C7 and at the gastrocnemial junction of both legs.